Haleos Labs Share Price Today (HALEOSLABS)
TODAY IN ONE LINE
HALEOSLABS fell 1.4%, in line with Nifty's -0.7% move.
With a market cap of ₹483.73 Cr., it trades at a P/E of 27.94. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Haleos Labs scorecard
Overall performance across 5 key dimensions.
Haleos Labs flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 72.1% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 15.7% YoY
- ●Poor Capital ReturnsLow ROE of 8.4%
Latest Haleos Labs News
What changed recently?
Recent events, corporate actions, and announcements.
Haleos Labs Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Haleos Labs Limited, framed against the sector median so the premium or discount is obvious at a glance.
Haleos Labs Limited trades at a P/E of 27.94× and P/B of 2.27×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Haleos Labs Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Haleos Labs Limited — derived from the live tape, not yesterday's close.
Haleos Labs Limited last traded at ₹1,548.4 with an intraday range of ₹1,515–₹1,570.4 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1548.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1685.00 | +136.60 | +8.82% |
| R3 | 1629.60 | +81.20 | +5.24% |
| R2 | 1600.00 | +51.60 | +3.33% |
| R1 | 1574.20 | +25.80 | +1.67% |
| PIVOT | 1544.60 | -3.80 | -0.25% |
| CURRENT | 1548.40 | — | — |
| S1 | 1518.80 | -29.60 | -1.91% |
| S2 | 1489.20 | -59.20 | -3.82% |
| S3 | 1463.40 | -85.00 | -5.49% |
| S4 | 1408.00 | -140.40 | -9.07% |
HALEOSLABS is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1550–₹1550
Trading Below opening range, showing Bearishness
Haleos Labs Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Haleos Labs Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Haleos Labs Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹483.73 Cr. and reported EPS of ₹57.30.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 345 | 334 ▼ 3.2% |
| Sales Growth YoY %Derived | 12.67% | -3.17% |
| Other Income | 5 | 2 ▼ 49.9% |
| Total Income | 350 | 336 ▼ 3.8% |
| 154 | 139 ▼ 10.1% | |
| Gross ProfitDerived | 191 | 195 ▲ 2.4% |
| Gross Margin %Derived | 55.31% | 58.50% |
| 146 | 151 ▲ 3.4% | |
| EBITDA (Operating Profit)Derived | 45 | 45 ▼ 0.8% |
| OPM %Derived | 13.07% | 13.38% |
| 24 | 22 ▼ 7.6% | |
| Profit Before Tax (PBT) | 26 | 25 ▼ 3.8% |
| 7 | 7 ▼ 0.8% | |
| Effective Tax %Derived | 28.47% | 29.35% |
| Total Profit for Period | 19 | 18 ▼ 5.0% |
| Less: Non-controlling Interests | -1 | 0 ▲ 135.5% |
| Net Profit (Owner's PAT)Derived | 20 | 17 ▼ 13.9% |
| Net Profit Margin %Derived | 5.83% | 5.19% |
| PAT Growth YoY %Derived | 121.15% | -13.91% |
| Earnings Per Share (EPS ₹) | 66.51 | 57.26 ▼ 13.9% |
| Diluted Shares Outstanding (Cr) | 0 | 0 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▼ 14.9% |
| Total Expenses (incl. D&A & Interest) | 323 | 311 ▼ 3.8% |
| Material Cost % of RevenueDerived | 43.49% | 43.95% |
| Employee Cost % of RevenueDerived | 17.27% | 19.59% |
| Other Cost % of RevenueDerived | 24.97% | 25.53% |
| Interest Coverage (x)Derived | 3.45x | 4.53x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 378 | 261 ▼ 31.0% | 266 ▲ 1.8% | 350 ▲ 31.7% | 316 ▼ 9.8% | 306 ▼ 3.0% | 345 ▲ 12.7% | 334 ▼ 3.2% | |
| Sales Growth YoY %Derived | — | -30.98% | 1.84% | 31.68% | -9.77% | -3.04% | 12.67% | -3.17% | |
| Other Income | 3 | 2 ▼ 10.4% | 2 ▼ 21.9% | 2 ▲ 16.0% | 3 ▲ 48.7% | 4 ▲ 24.6% | 5 ▲ 27.0% | 2 ▼ 49.9% | |
| Total Income | 380 | 263 ▼ 30.8% | 267 ▲ 1.6% | 352 ▲ 31.6% | 319 ▼ 9.4% | 310 ▼ 2.8% | 350 ▲ 12.8% | 336 ▼ 3.8% | |
256 | 158 ▼ 38.3% | 137 ▼ 13.2% | 195 ▲ 42.1% | 171 ▼ 12.0% | 151 ▼ 11.8% | 154 ▲ 1.9% | 139 ▼ 10.1% | ||
| Gross ProfitDerived | 122 | 103 ▼ 15.6% | 129 ▲ 24.9% | 155 ▲ 20.6% | 144 ▼ 7.0% | 155 ▲ 7.4% | 191 ▲ 23.2% | 195 ▲ 2.4% | |
| Gross Margin %Derived | 32.28% | 39.46% | 48.40% | 44.33% | 45.68% | 50.59% | 55.31% | 58.50% | |
87 | 78 ▼ 11.2% | 98 ▲ 26.9% | 121 ▲ 22.9% | 115 ▼ 4.5% | 124 ▲ 7.2% | 146 ▲ 17.7% | 151 ▲ 3.4% | ||
| EBITDA (Operating Profit)Derived | 35 | 25 ▼ 26.9% | 30 ▲ 18.9% | 34 ▲ 13.2% | 29 ▼ 15.8% | 31 ▲ 8.2% | 45 ▲ 44.8% | 45 ▼ 0.8% | |
| OPM %Derived | 9.19% | 9.73% | 11.36% | 9.76% | 9.11% | 10.17% | 13.07% | 13.38% | |
12 | 13 ▲ 9.3% | 12 ▼ 4.7% | 29 ▲ 133.0% | 20 ▼ 31.0% | 25 ▲ 25.9% | 24 ▼ 5.5% | 22 ▼ 7.6% | ||
| Profit Before Tax (PBT) | 25 | 15 ▼ 42.2% | 20 ▲ 33.4% | 33 ▲ 67.3% | 17 ▼ 49.3% | 10 ▼ 40.7% | 26 ▲ 166.0% | 25 ▼ 3.8% | |
8 | 4 ▼ 40.5% | 6 ▲ 34.0% | 7 ▲ 23.6% | 5 ▼ 29.8% | 4 ▼ 32.5% | 7 ▲ 111.9% | 7 ▼ 0.8% | ||
| Effective Tax %Derived | 29.69% | 30.58% | 30.72% | 22.70% | 31.43% | 35.74% | 28.47% | 29.35% | |
| Total Profit for Period | 18 | 10 ▼ 42.9% | 14 ▲ 33.1% | 25 ▲ 86.5% | 11 ▼ 55.0% | 6 ▼ 44.4% | 19 ▲ 196.0% | 18 ▼ 5.0% | |
| Less: Non-controlling Interests | — | — | — | — | -0 | -3 ▼ 2789.2% | -1 ▲ 50.2% | 0 ▲ 135.5% | |
| Net Profit (Owner's PAT)Derived | 18 | 10 ▼ 42.9% | 14 ▲ 33.1% | 25 ▲ 86.5% | 11 ▼ 54.6% | 9 ▼ 20.7% | 20 ▲ 121.2% | 17 ▼ 13.9% | |
| Net Profit Margin %Derived | 4.72% | 3.90% | 5.10% | 7.23% | 3.64% | 2.97% | 5.83% | 5.19% | |
| PAT Growth YoY %Derived | — | -42.94% | 33.13% | 86.46% | -54.61% | -20.75% | 121.15% | -13.91% | |
| Earnings Per Share (EPS ₹) | 59.03 | 33.68 ▼ 42.9% | 44.84 ▲ 33.1% | 83.61 ▲ 86.5% | 37.92 ▼ 54.6% | 30.08 ▼ 20.7% | 66.51 ▲ 121.1% | 57.26 ▼ 13.9% | |
| Diluted Shares Outstanding (Cr) | 0 | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | -0 | — ▲ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 1126.3% | -0 ▲ 76.5% | -0 ▲ 51.1% | 0 ▲ 167.7% | -0 ▼ 1970.0% | 0 ▲ 128.8% | 0 ▼ 14.9% | |
| Total Expenses (incl. D&A & Interest) | 355 | 248 ▼ 30.0% | 248 ▼ 0.2% | 319 ▲ 28.8% | 302 ▼ 5.3% | 300 ▼ 0.7% | 323 ▲ 7.8% | 311 ▼ 3.8% | |
| Material Cost % of RevenueDerived | 71.14% | 56.39% | 50.89% | 58.46% | 54.29% | 49.09% | 43.49% | 43.95% | |
| Employee Cost % of RevenueDerived | 6.12% | 10.19% | 11.54% | 11.41% | 13.76% | 16.10% | 17.27% | 19.59% | |
| Other Cost % of RevenueDerived | 16.97% | 19.54% | 25.50% | 23.16% | 22.81% | 24.32% | 24.97% | 25.53% | |
| Interest Coverage (x)Derived | 5.15x | 3.41x | 4.93x | 3.91x | 2.64x | 1.59x | 3.45x | 4.53x |
Haleos Labs segment analysis : revenue and profit mix.
Disclosed business segments at Haleos Labs with their share of revenue and profit, switchable between consolidated and standalone reporting.
Haleos Labs discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Haleos Labs Limited.
Our AI distills the core fundamental drivers supporting Haleos Labs Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 36 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.02. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Haleos Labs Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Haleos Labs Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Haleos Labs Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Haleos Labs Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Haleos Labs Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Haleos Labs Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Haleos Labs Limited stood at 64.1% of traded volume, against a 20-day average of 59.6%.
Haleos Labs announcements: results, concalls, ratings, M&A.
Filings Haleos Labs sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Haleos Labs files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 61 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
HALEOS LABS LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
HALEOS LABS LIMITED has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Updates
HALEOS LABS LIMITED has informed the Exchange regarding 'Sub-Committees Of Board (Reconstitution)'.
Copy of Newspaper Publication
HALEOS LABS LIMITED has informed the Exchange about Copy of Newspaper Publication
Dividend
HALEOS LABS LIMITED has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 1.50 per…
Investor decks & rating reports.
Haleos Labs dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Haleos Labs has declared, sequenced by announce and record date.
Haleos Labs corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Haleos Labs Limited: business, sector, key facts.
What Haleos Labs Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Haleos Labs Limited is a listed Indian equity, listed as NSE: HALEOSLABS, BSE: 540679.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Haleos Labs Limited (HALEOSLABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Haleos Labs Limited (HALEOSLABS)?
The current share price of Haleos Labs Limited (HALEOSLABS) is ₹1,548.4. Today, the stock has declined by ₹22.60 (1.44%), trading in a range of ₹1,515 to ₹1,570.4. The stock opened at ₹1,550 with a trading volume of 106 shares.
02Is Haleos Labs Limited stock a good investment for long-term?
Haleos Labs Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹483.73 crores, P/E ratio of 27.94, ROE of 8.44%, and ROCE of 9.91%. The dividend yield stands at 0.10%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Haleos Labs Limited stock?
The 52-week high price of Haleos Labs Limited (HALEOSLABS) is ₹1,774, while the 52-week low is ₹1,181. Currently trading at ₹1,548.4, the stock is 62.0% away from its 52-week low and 12.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Haleos Labs Limited stock at the current price?
Whether to buy Haleos Labs Limited stock at ₹1,548.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.94 and P/B ratio of 2.27. Today's performance shows a loss of 1.44%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Haleos Labs Limited and when is the next dividend?
Haleos Labs Limited offers a dividend yield of 0.10%, which means for every ₹100 invested at the current price of ₹1,548.4, you can expect to receive approximately ₹0.10 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Haleos Labs Limited?
Haleos Labs Limited's key financial metrics include: P/E Ratio: 27.94, P/B Ratio: 2.27, ROE: 8.44%, ROCE: 9.91%, Dividend Yield: 0.10%, EPS: ₹57.30, Book Value: ₹706, and Debt-to-Equity: 0.52. The company's market cap stands at ₹483.73 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Haleos Labs Limited stock performing today in the market?
Haleos Labs Limited stock opened at ₹1,550 and is currently trading at ₹1,548.4, showing a decline of ₹22.60 (1.44%). The intraday high is ₹1,570.4 and low is ₹1,515. The trading volume stands at 106 shares, indicating moderate market participation today.
08What is the P/E ratio of Haleos Labs Limited and what does it indicate?
Haleos Labs Limited has a Price-to-Earnings (P/E) ratio of 27.94, which means investors are willing to pay ₹27.94 for every ₹1 of earnings. With an EPS of ₹57.30, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Haleos Labs Limited (HALEOSLABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.